Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial
T A Lalmahomed, E M Monninkhof, M J van Rijssel, H H E van Melick, H M Verkooijen, J C J de Boer, J R N van der Voort van Zyp · 2025
Read Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial by T A Lalmahomed, E M Monninkhof, M J van Rijssel, H H E van Melick, H M Verkooijen, J C J de Boer, J R N van der Voort van Zyp (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751598.txt.
Description
Lalmahomed and co-authors lay out a trial testing whether prostate cancer radiation can shrink from five sessions to two. Standard care for middle-risk, localized disease already fell from thirty-five sessions to five, with good results. Their 2025 protocol uses MRI-guided machines that aim dose precisely, sparing bladder and bowel.
One hundred sixty patients will be split evenly. The control group gets the standard five sessions over about two weeks. The test group gets two large sessions in eight days, with an extra boost on the visible tumor. The main check is moderate urinary side effects within ninety days. Later checks cover bowel effects, quality of life, and cancer control out to five years. Data ride on an existing outcomes registry.
Catalog record
| CREATOR | T A Lalmahomed, E M Monninkhof, M J van Rijssel, H H E van Melick, H M Verkooijen, J C J de Boer, J R N van der Voort van Zyp |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |